These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 33485119)
1. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Katebi A; Varshochian R; Riazi-Rad F; Ganjalikhani-Hakemi M; Ajdary S Biomed Pharmacother; 2021 May; 137():111276. PubMed ID: 33485119 [TBL] [Abstract][Full Text] [Related]
2. 4-nitrochalcone exerts leishmanicidal effect on L. amazonensis promastigotes and intracellular amastigotes, and the 4-nitrochalcone encapsulation in beeswax copaiba oil nanoparticles reduces macrophages cytotoxicity. Assolini JP; da Silva TP; da Silva Bortoleti BT; Gonçalves MD; Tomiotto-Pellissier F; Sahd CS; Carloto ACM; Feuser PE; Cordeiro AP; Sayer C; Hermes de Araújo PH; Costa IN; Conchon-Costa I; Miranda-Sapla MM; Pavanelli WR Eur J Pharmacol; 2020 Oct; 884():173392. PubMed ID: 32735985 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice. Rostamian M; Niknam HM Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929 [TBL] [Abstract][Full Text] [Related]
4. PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB/c mice. Katebi A; Riazi-Rad F; Varshochian R; Ajdary S Int Immunopharmacol; 2024 Jun; 138():112538. PubMed ID: 38924865 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice. Rostamian M; Bahrami F; Niknam HM PLoS One; 2018; 13(9):e0204491. PubMed ID: 30248142 [TBL] [Abstract][Full Text] [Related]
6. PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania. Santos DM; Carneiro MW; de Moura TR; Soto M; Luz NF; Prates DB; Irache JM; Brodskyn C; Barral A; Barral-Netto M; Espuelas S; Borges VM; de Oliveira CI Nanomedicine; 2013 Oct; 9(7):985-95. PubMed ID: 23603355 [TBL] [Abstract][Full Text] [Related]
7. Resistance Against Lopes ME; Dos Santos LM; Sacks D; Vieira LQ; Carneiro MB Front Immunol; 2021; 12():730437. PubMed ID: 34745100 [TBL] [Abstract][Full Text] [Related]
8. Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection. Pandey SP; Chandel HS; Srivastava S; Selvaraj S; Jha MK; Shukla D; Ebensen T; Guzman CA; Saha B J Immunol; 2014 Oct; 193(7):3632-43. PubMed ID: 25194056 [TBL] [Abstract][Full Text] [Related]
9. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. Valadares DG; Duarte MC; Oliveira JS; Chávez-Fumagalli MA; Martins VT; Costa LE; Leite JP; Santoro MM; Régis WC; Tavares CA; Coelho EA Parasitol Int; 2011 Dec; 60(4):357-63. PubMed ID: 21723957 [TBL] [Abstract][Full Text] [Related]
10. Nano-co-delivery of lipophosphoglycan with soluble and autoclaved leishmania antigens into PLGA nanoparticles: Evaluation of in vitro and in vivo immunostimulatory effects against visceral leishmaniasis. Tosyali OA; Allahverdiyev A; Bagirova M; Abamor ES; Aydogdu M; Dinparvar S; Acar T; Mustafaeva Z; Derman S Mater Sci Eng C Mater Biol Appl; 2021 Jan; 120():111684. PubMed ID: 33545846 [TBL] [Abstract][Full Text] [Related]
11. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses. Srivastava S; Pandey SP; Jha MK; Chandel HS; Saha B Clin Exp Immunol; 2013 Jun; 172(3):403-9. PubMed ID: 23600828 [TBL] [Abstract][Full Text] [Related]
12. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge. Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328 [TBL] [Abstract][Full Text] [Related]
13. Nanoparticles Loaded with a New Thiourea Derivative: Development and Meireles PW; de Souza DPB; Rezende MG; Borsodi MPG; de Oliveira DE; da Silva LCRP; de Souza AMT; Viana GM; Rodrigues CR; do Carmo FA; de Sousa VP; Rossi-Bergmann B; Cabral LM Curr Drug Deliv; 2020; 17(8):694-702. PubMed ID: 32621717 [TBL] [Abstract][Full Text] [Related]
14. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions. Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731 [TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan. Halliday A; Bates PA; Chance ML; Taylor MJ Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391 [TBL] [Abstract][Full Text] [Related]